Mirum Pharma Raises 2026 Guidance to $715-720M: Rare Pediatric Liver Disease Drug Scales

The Quick Take

• Mirum Pharmaceuticals (MIRM) raised full-year 2026 net product sales guidance to $715-720 million after Q3 sales of $186 million — 9-month revenue already matching all of 2025.
• MIRM's growth is driven by its rare pediatric liver disease portfolio, particularly LIVMARLI (maralixibat) for Alagille syndrome and other cholestatic conditions.
• The acceleration of rare disease revenues signals that MIRM has achieved commercial scale in a highly defensible market segment with limited competition.

Mirum Pharmaceuticals' guidance raise to $715-720 million for 2026 is extraordinary for a company that only achieved these levels of revenue in full-year 2025. The 9-month 2026 revenue already matching the entire prior year implies roughly 30%+ annualised growth — driven primarily by LIVMARLI (maralixibat), which treats cholestasis and pruritus in rare pediatric liver diseases. Rare disease drugs benefit from durable pricing power, long patient treatment durations, and minimal competition from generics given market size constraints.

MIRM's commercial model is built on serving the pediatric cholestasis patient population — extremely small but underserved by the medical system before LIVMARLI's approval. The drug's mechanism (inhibiting the ileal bile acid transporter to reduce bile acid accumulation in the liver) is the first approved treatment of its kind for Alagille syndrome, giving MIRM first-mover advantage and near-monopoly positioning. Market expansion opportunities exist in additional rare liver disease indications beyond the initial approval.

India context: India has a significant undiagnosed pediatric liver disease burden, and rare disease treatments like LIVMARLI are progressively being introduced through orphan drug programmes. Indian pharma companies (Sun Pharma, Cipla) are increasingly investing in rare disease portfolios. MIRM's commercial success validates the rare pediatric disease market as sustainable — a signal that Indian companies with rare disease pipelines can achieve meaningful commercial scale if they target similar high-unmet-need conditions.

Synthesized from 1 source.